Inotuzumab Ozogamicin

A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2017
0102020042017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab… (More)
  • table 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Survival is poor in pediatric patients with relapsed or refractory acute B-cell lymphoblastic leukemia (ALL) and therapeutic… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a CD22… (More)
Is this relevant?
2013
2013
BACKGROUND No highly effective salvage therapy exists for patients with relapsed acute lymphoblastic leukemia (ALL). Inotuzumab… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
B cells participate in the priming of the allo- and autoimmune responses, and their depletion can thus be advantageous for islet… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
We investigated whether the newly developed antibody (Ab) -targeted therapy inotuzumab ozogamicin (CMC-544), consisting of a… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody… (More)
Is this relevant?
2010
2010
Inotuzumab ozogamicin (CMC-544), an antibody-targeted chemotherapeutic agent composed of an anti-CD22 antibody conjugated to… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2007
2007
CMC-544 (inotuzumab ozogamicin) is a CD22-specific cytotoxic immunoconjugate of calicheamicin intended for the treatment of B… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?